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Objective: Role of superficial venous surgery in reducing the time it takes for ulcers to heal is still controversial, although
all studies confirm a significant reduction in ulcer recurrences. Recently, the HFE-C282Y and FXIII-V34L gene variants
demonstrated a role in the risk of venous ulceration in primary chronic venous disorder (CVD) and in modulating lesion
size in chronic venous ulcer (CVU), respectively. This study was conducted to investigate the role of HFE-C282Y and
FXIII (V34L and P564L) gene variants in ulcer healing time after superficial venous surgery, by assessing the outcome of
a cohort of homogeneous CVU patients.
Methods: The study selected 91 patients affected by primary CVU (CEAP C6, Ep, Asp, Pr), with the exclusion of any other
comorbidity factor involved in delayed healing process, who underwent surgery. We assessed the ulcer area and the healing
time. Patients were genotyped by polymerase chain reaction for FXIII (V34L and P564L) and forHFE-C282Y substitutions.
Results: Globally, CVU cases had a postoperative mean healing time of 8.5  5.7 weeks. For the subset of cases above and
below the median value (M 8.0 weeks), FXIII-V34L genotype distribution significantly differed (P< .0001). In addition,
Kaplan-Meier analysis yielded specific healing timeprofiles for the differentFXIII-V34L classes of genotype (P .00001),with
an increased risk of delayed healing for the FXIII-VV genotype (hazard ratio, 4.14; 95% confidence interval, 2.1 to 8.2; P 
.00005). AlthoughFXIII-P54L genotype distributions did not differ, homozygous 564LL cases (P .005) and double carriers
for both FXIII variants (P < .0001), had a significantly reduced healing time vs wild types. No differences in healing
time were observed between carriers and noncarriers of the HFE-C282Y variant, whereas when these cases were
stratified by FXIII-V34L genotypes, the L34 carriers had a significantly shorter healing time, irrespective of theHFE
genotype.
Conclusion: The FXIII-34L variant was significantly associated with shorter healing time after superficial venous surgery,
suggesting a role in the healing and tissue regeneration phases. Conversely, HFE-C282Y, despite its role in ulcer
establishment, did not affect the postoperative healing time. In perspective, the identification of patients with a poor
prognosis may give clinicians the opportunity to modify management and to target tailored therapies in the view of a new
and alternative concept of treatment based on pharmacogenomics. ( J Vasc Surg 2006;44:554-62.)Chronic venous leg ulcers (CVU), account for a signif-
icant proportion of lower extremity wounds. CVU is a
severe clinical manifestation of chronic venous disease
(CVD), a widespread pathologic condition in developed
countries.1,2 CVD accounts for about 70% of CVU, and
although it is an essential comorbidity factor, it is insuffi-
cient for skin lesion appearance.2-4 The prevalence of CVU
in the United States and Europe is 0.5% to 2.0%, with very
high health-service and socioeconomic costs owing to the
frequent recurrences and repercussions on the patients’
capabilities to work.5
The treatment of choice for CVU is compression ban-
daging combined with wound bed preparation. For those
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554patients who do not improve with conventional care, skin
grafting or biologic dressing are useful.2,6 Whilst it is con-
troversial if the addition of superficial venous reflux correc-
tion by surgery has positive effects in reducing ulcer healing
time, there is wider agreement in the associated reduction
of recurrences.7,8 The Comparison of Surgery and Com-
pression with Compression Alone in Chronic Venous Ul-
ceration (ESCHAR) study compared healing and recur-
rence rates in CVU patients treated with compression, with
or without surgery.9 It concluded that superficial venous
surgery confers no added benefit over compression in heal-
ing rate but does lead to a reduction in recurrence, accord-
ing to other nonrandomized studies.8
A recent systematic review that evaluated the overall
rates of clinical outcomes in patients with severe CVD
concluded that surgery, subfacial endoscopic perforator
surgery included, with or without saphenous ablation, leads
to an 88% chance of ulcer healing and a 13% chance of
recurrence.10 The authors concluded that randomized
controlled trials were needed to define the effective con-
tributors of compression, superficial surgery, and subfacial
endoscopic perforator surgery in CVU treatment.
Finally, we published a randomized study that com-
pared the effects on healing of minimally invasive surgical
intervention vs compression, exclusively reserved for pa-
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in absence of other significant comorbidities.11 We con-
cluded that this kind of hemodynamic correction, respect-
ing the proposed indications, improves healing even in
terms of time, recurrence, and hemodynamics.
Regardless of the clinical strategy, a great variation
exists in the clinical outcome among patients with similar
disease pattern and treatment. Owing to the multifactorial
etiology of longstanding ulcer, recognizing appropriate risk
factors affecting healing may be a choice strategy to early
select those patients that will have an unfavorable outcome.
A recent study identified among a number of routinely
assessed variables, increased patient age and ulcer chronic-
ity, and slow healing time, but not surgically treated super-
ficial venous reflux, as independent risk factors, respec-
tively, for healing and recurrence.12 In addition, larger
wound area, duration of the wound, and fibrin on50% of
the lesion surface were associated with failure to heal.13
Other good candidate risk factors, such as diabetes, rheu-
matoid arthritis, or popliteal vein incompetence, were not
found to be significantly associated.12 This clarifies the
current lack of understanding in venous ulcer pathogenesis.
On the other hand, many patients with CVD do not
progress towards skin lesion, suggesting that interindi-
vidual variability is warranted. Genetics may have a role in
subject individuality, although evidences for this and for a
mode of inheritance are lacking.
We recently recognized that the common gene poly-
morphisms HFE-C282Y and FXIII-V34L have a role, re-
spectively, in increasing the risk of venous ulceration by
establishing local iron overload in primary CVD pa-
tients,14,15 and in modulating the lesion size by means of
positive effects on fibroblast cells and extracellular matrix
components in CVU patients.16
The HFE-C282Y variant in the coding region of the
hemochromatosis gene affects iron metabolism. Heterozy-
gous subjects are generally considered asymptomatic carri-
ers unless other inherited or acquired conditions may con-
textually determine iron overload.17
FXIII-V34L, in the coding region of the coagulation
factor XIII gene, significantly increased the transglutami-
nase activity of the molecule in a gene-dosage effect. Basi-
cally, the FXIII-V34L variant decreases the risk of throm-
bosis, and recent in vitro and in vivo studies ascribed to
FXIII, or to its variants, a key role in wound healing, tissue
repairing/remodelling and angiogenesis.18 Other FXIII
gene variants, such as FXIII-P564L, may affect the mole-
cule properties, but very few and conflicting data have been
reported.19 Therefore, in the present study we investigated
whether these recognized gene factors might have effects
on the healing time of CVUpatients after superficial venous
surgery.
PATIENTS AND METHODS
Patient population. We studied 91 patients (65%
women) with a mean age of 60.5  14.5 years who were
affected by primary CVU involving exclusively the superfi-
cial and perforator vein system. Patients were selected froman initial cohort of 215 patients referred to our Vascular
Diseases Center. For the purpose of patient selection, these
patients had a clinical history recorded and a duplex scan-
ning examination. These investigations, conducted in ac-
cordance with consensus statement criteria and a method-
ology previously described,11,22,23 allowed us to carefully
separate primary superficial from secondary cases, and
within the latter, those affected by post-thrombotic venous
insufficiency, and also to identify patients with peripheral
arterial disease.
The following exclusion criteria for patient selection
were strictly applied to exclude any other comorbidity
factor that might potentially be involved in delayed wound
healing: diabetes, peripheral arterial disease or an ankle-
brachial index 0.9, or both; hemolytic anemia, iron-
deficiency anemia, or malnutrition; inability to walk, severe
cardiac, hepatic, renal, or pulmonary insufficiency; long-
term administration of cortisones for chronic inflammatory
disease or autoimmune disease, duration of the skin lesion
6-months, and post-thrombotic syndrome.
After applying the criteria, 91 patients were selected,
described by the following CEAP algorithm:C6s, Ep, As2 3
4 5-p 17 18, Pr. The area of the ulcer was digitally acquired
and then assessed by means of software that was able to
calculate any irregular area (Visitrak Capture, Smith &
Nephew, London, UK). Finally, patients underwent pre-
operative air plethysmography assessment of venous func-
tion.
Surgical treatment. The selected patients underwent
hemodynamic correction of superficial venous reflux ac-
cording to a technique previously reported and validated by
a long-term randomized trial of venous ulcer treatment.11
On admission, the operation was planned for a week later
and the patients, while waiting, were immediately treated
with compression bandaging. Operations were performed
in the Day-Surgery Unit with local anesthesia and required
preoperative duplex mapping. Surgical débridement was
performed in the same session.
In the case of patients with infected wounds, the antimi-
crobial susceptibility test was ordered and wide-spectrum
antibiotics were administered; they were replaced after 5 days
by a specific antibiotic as indicated by the test results.
The primary cover of the ulcer was an advanced dress-
ing (Actisorb plus 25, Johnson & Johnson, Berkshire, UK,
or Hyalofil, Fidia Advanced Biopolymers [FAB], Padova
Italy). The bandaging was changed every 3 to 5 days during
the first month of treatment and then every 7 days. Once
the ulcers were healed, the patients were fitted for elastic
stockings exerting 20 to 30 mm Hg of compression at the
ankle.
Surgical procedure details. Two different minimally
invasive techniques were performed, according to the loca-
tion of the superficial opening of the re-entry perforator
vein (RPV). The RPV is defined as a perforator in which
finger compression above its opening is able to eliminate
the reflux wave in the saphenous trunk. Such an opening
can be located either on the long saphenous vein-short
saphenous vein main trunk (type I shunt) or on a long
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shunt). A duplex assessment, which was performed for both
procedures, can easily differentiate between the two main
hemodynamic presentations.20,21
The operation for the type I presentation was a classic
high ligation of the saphenofemoral junction or saphe-
nopopliteal junction plus flush ligation and division from
saphenous trunk of the insufficient T (Fig 1, A). It was
performed in 72 cases (79.1%). Patients began to walk 1
hour after the procedure. The ulcer was covered by an
advanced dressing, and the patient wore an elastic stocking
exerting 20-30 mm Hg of ankle pressure.
The operation for the type II presentation was a flush
ligation and division from the saphenous trunk of the
insufficient T, which contains the RPV (Fig 1, B). The
postoperative course was the same as described for the type
I shunt.
Measurements. The clinical result assessment was
made in a blinded fashion to the genotype of patients and
according to the following parameters:
● Healing process. The process of healing was assessed
by measuring changes in area of the lesions at the
subsequent visits, as described above. The rate of re-
currence was also assessed whenever appropriate.
● Duplex scanning. To assess reflux recurrences, com-
plete venous duplex scanning was performed 6months
later with the patient standing and the reflux elicited by
calf manual squeezing.
● Venous function. The selected patients underwent
air-plethysmography (APG) (ACI Medical, Sun Val-
ley, Calif), an evaluation of total venous volume (VV),
venous filling index (VFI), ejection fraction (EF), and
residual volume fraction (RVF) preoperatively and 6
months postoperatively at the same hour and temper-
ature condition (between 8:00 AM and 10:00 AM at
23° C).
DNA analysis. Genomic DNA was isolated from pe-
ripheral blood by using standard proteinase-K treatment,
followed by phenol-chloroform extraction and ethanol pre-
cipitation. Polymerase chain reaction was used to genotype
samples for FXIII-V34L, FXIII-P564L, and HFE-C282Y
gene variants according to previous reports.24-26 Geno-
types were confirmed by re-genotyping a random selection
of samples for each polymorphism investigated. No dis-
crepancies were found between genotypes determined in
duplicate. Genotyping was done in a blinded fashion rela-
tive to the clinical phenotype and the healing progress of
patients.
Statistical analysis. The statistical significance for the
differences between case groups was performed by Stu-
dent’s t test for parametric data and 2 for nonparametric
data. Where appropriate, the Yates correction or Fisher’s
exact test was applied. P  .05 was considered statistically
significant. To estimate the risk of having a poor clinical
outcome in terms of healing time greater than the median
value, hazard risk (HR) and 95% confidence intervals (95%
CI) were calculated between different classes of genotypesbymeans of Cox proportionate hazardsmodeling, with and
without the enclosure of confounding factors such as sex,
age, and mutual genotype adjustments. Healing time pro-
files for cases with different classes of genotype were simi-
larly obtained by Kaplan-Meier analysis, and differences
were determined by using a log-rank test. All analyses were
performed with Systat 5.0 (Systat Inc, Evanston, Ill) and
Fig 1. A, Hemodynamic correction procedure performed for
type I presentation. Left panel: reflux from the saphenofemoral
junction (SFJ) flows downward along the main saphenous trunk
(GSV) to the varicose tributary (T) and to the re-entry perforating
vein (RPV). Right panel: operation consisted in flush legation and
disconnection of the GSV from the femoral vein, and of the T from
the GSV. We eliminated in this way the reflux point with change of
compartments from deep to saphenous compartment, and from
saphenous compartment to the superficial one, respectively. In the
GSV, we so obtained a reverse flow from the junction to the RPV,
and a forward flow from the foot to the RPV. Air-plethysmography
parameters assessed the effectiveness of the procedure.20 B. He-
modynamic correction procedure performed for type II presenta-
tion. Left panel: reflux from the SFJ flows downward along the
GSV to the T without re-entry perforating vein detectable along
the GSV. Right panel: operation consisted in flush legation and
disconnection of the T from the GSV. In the GSV, we also
obtained a forward flow. Air-plethysmography parameters assessed
the effectiveness of the procedure.21the SPSS 10.1 statistical software (SPSS Inc, Chicago, Ill).
an 
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Clinical results. The 91 ulcerated lower extremities
that were related to a primary and superficial venous disor-
der had the hemodynamic correction procedure in our
Day-Surgery Unit. Patients were discharged 3 hours and
were seen twice a week for the first week and then weekly
until the ulcer was healed. Patient follow-up lasted about 6
months. The healing rate was 100% in the 6-month period.
Duplex assessment. Duplex imaging allowed the cor-
rectness of the operations for type I and type II presenta-
tions to be assessed according to the schema presented in
Fig 1, A and B.
Venous function. All the APG parameters (VV, VFI,
and RVF), with the exception of EF, significantly improved
6 months after the operation, confirming the surgical res-
toration of venous hemodynamics (Table I).
FXIII-V34L and FXIII-P564L gene variants and
ulcer healing time. Table II summarizes the genotype
distribution of the FXIII- and HFE- gene polymorphisms
stratified above and below the median healing time value of
8 weeks. The FXIII-V34L distribution was significantly
different (P  .0001), accounting for the significant over-
representation of L34 carriers found in patients with shorter
healing times (27/39, 69.3%) vs those with longer healing
times (16/52, 30.7%, P .0001) (Fig 2). In explorative
analysis, this yielded an overall crude estimate of the risk to
have a delayed healing time of about five times for theVV34
genotype vs L34 carriers in our population (HR, 5.06; 95%
CI, 2.06 to 12.4; P .0001). When confounding variables
and the other gene variants were entered in the Cox regres-
sion model, the risk estimate did not change the output
Table I. Air-plethysmography parameter assessment
APG assessment VV mL/air
Pre-op 170  54.6
6 months post-op 134  44.1*
(25%)
APG, Air-plethysmography; VV, total venous volume; VFI, venous filling in
Preoperative and 6 months post-operative APG parameters expressed as me
*Postoperative parameters significantly different compared with preoperativ
Table II. Comparison of polymorphism genotype distribu
above and below the median value.
FXIII-V34L P FXIII
HT M (n52) HT M (n52)
VV 36 (69.2) PP
VL 11 (21.1) PL
LL 5 (9.6) LL
HT M (n  39) .0001 HT M (n  39
VV 12 (30.7) PP
VL 24 (61.5) PL
LL 3 (7.7) LL
HT, Healing time; M, median.
Data are numbers and percentages (%)(HR, 4.14; 95% CI, 2.08 to 8.23; P  .0001).The evaluation for differences in the healing time pro-
files for the two classes of FXIII-V34L genotype was done
by Kaplan-Meier analysis. It showed significant differences
and ascribed to the FXIII-VV genotype the worst clinical
outcome in terms of greater percentage of cases with heal-
ing times above the median (log-rank test, P  .00001)
(Fig 3). No significantly different distributions were found
with the FXIII-P564L gene variant.
Together with the significant overrepresentation in the
number of L34 carriers found in the group with healing
times below the median, a significantly shorter mean heal-
ing time was also found in the L-34 carrier group (ie, 6.2
3.4 weeks vs 10.6 6.5 weeks, P .0001, respectively, for
the L34 and the VV34 carriers; see Table III). In these two
subgroups of patients, we also assessed the dimension of the
ulcer area, and as expected, we found that it was signifi-
cantly smaller in the L34 carriers than in the VV34 carriers
(6.0 6.2 cm2 vs 13.1 24.5 cm2, P .029; respectively;
see Table III).
Results with a similar trend were found with the
FXIII-P564L gene polymorphism but with nonsignifi-
cant or borderline values (Table III). In explorative
analysis computing merely the 564LL homozygotes, they
had both mean healing time (5.7 1.9 weeks, P .005)
and ulcer area (2.83  1.3 cm2, P  .003) significantly
lower than that found in the wild types (data not shown).
To minimize the predictable effects of ulcer dimen-
sion on healing time and to better assess and define the
effective genotype contribution, we considered patients
above and below the median healing time as two separate
groups. We found significant results only in the sub-
L/s EF % of VV RVF % of VV
3.4 48  12.5 40  15.7
51* 57.0  18.1 29  15.1*
4%) (31%)
F, ejection fraction; RVF, residual volume fraction.
SD. In parenthesis are reported the rate of postoperative variations.
ssments (P  .001).
s between chronic venous ulcer patients with healing time
L P HFE-C282Y P
HT M (n52)
29 (55.7) CC 47 (90.4)
21 (40.4) CY 5 (9.6)
2 (3.8) YY 0 (0)
.29 HT M (n  39) .885
24 (61.5) CC 34 (87.2)
11 (28.2) CY 5 (12.8)
4 (10.2) YY 0 (0)VFI m
6.7 
3.0 
(4
dex; Etion
-P564
)group with a larger ulcer area. In particular, patients with
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(Table IV, top). It is noteworthy that also in the absence
of significant differences in mean ulcer size between
patients with the FXIII-V34L genotype (P  .08), pa-
Fig 2. Healing time and FXIII-V34L polymorphism distribution
in the whole cohort of patients with chronic venous ulcer investi-
gated in the study. L34 carriers indicate cases with FXIII-VL34 or
FXIII-LL34 genotype. The line indicates a median healing time of
eight weeks. The P value indicates the statistical significance be-
tween the percentage of FXIII-L34 carriers in cases with healing
time above and below the median.
Fig 3. Kaplan-Meier analysis for chronic venous ulcer patients
stratified by FXIII-V34L genotypes (log-rank test, P .00001).tients carrying the L34 allele had a significantly shorterhealing time (P  .017; see Table IV, top). With the
FXIII-P564L variant, borderline significant values were
obtained between different genotypes for both mean
healing time and ulcer size (Table IV, top). Conversely,
absolutely no significant results or trend were obtained
in the group with smaller ulcer area (Table IV, bottom).
Fig 4 clearly summarizes the relationships between mean
healing time and different FXIII genotypes.
In addition, to investigate possible combined effects
on healing time of the two FXIII gene polymorphisms,
the 18 subjects carrying both gene variants were com-
pared with the 28 subjects null for both the polymorphic
alleles. The different healing time distributions of the
two subgroups of cases are shown in Fig 5, with signifi-
cantly shorter mean healing times found in double car-
riers compared with wild types (5.8  2.1 weeks vs 10.9
 6.9 weeks, P  .0001).
HFE-C282Y gene variant and ulcer healing time.
The genotype distribution of theHFE gene polymorphism
stratified above and below the median healing time was not
significantly different (Table II). Similarly, the mean heal-
ing time and themean ulcer area were both nonsignificantly
different comparing HFE-C282Y carriers vs noncarriers in
the whole group of cases, as well as in the subset groups that
were analyzed (data not shown). Finally, stratifying these
cases by FXIII-V34L genotypes, the L34 carriers conserved
the significative shorter healing time, irrespective of the
HFE-C282Y genotype (Table V).
DISCUSSION
Many of the limitations in the treatment of CVU are
due to the lack of knowledge of molecular wound healing
mechanisms. To identify a number of independent inher-
ited or required risk factors responsible for chronic wound
pathogenesis is an essential step for the diagnosis and
prevention of such a complex disease and for the design of
new treatment strategies as alternatives or ancillary to the
standard procedures. Apart from CVD, increasing age and
female gender,2-4 clear evidences for genetic predisposition
to CVU are still limited. Candidate genes may be those
involved in inflammatory processes, fibroblast growth fac-
tors, angiogenesis, or apoptosis. Very few data on single
nucleotide polymorphisms and CVU are available in the
literature.27-29 We recently recognized that the common
single nucleotide polymorphisms HFE-C282Y and FXIII-
V34L have a role, respectively, in the risk of venous ulcer-
ation in primary CVD and in the modulation of the lesion
size of CVU patients.14-16
The main finding of our study was that among our
cohort of patients affected by primary CVU who under-
went superficial venous surgery, the FXIII-VV34 genotype
was a predictor for poor clinical outcome in terms of longer
healing time, and confirmed also in combination with the
FXIII-PP564 genotype. In explorative monovariate analy-
sis, the risk was about five times (odds ratio, 5.0; 95% CI,
2.06 to 12.4) for VV34 patients, and it also remained
significant in multivariate analysis (HR, 4.14; 95% CI, 2.08
to 8.23).
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area, a risk factor previously described as being associated
with failure of wounds to heal.13 In that study, authors
observed that the failure of a wound to heal 24 weeks of
limb compression was associated with the initial area of the
lesion along with other risk factors. This could partly affect
our findings. However, the clearly significant shorter heal-
ing time (P .017) in the cohort of our patients who were
L34 carriers, also in the presence of nonsignificant different
mean wound areas between the opposite genotypes (P 
.08), improves our outcome.
On the other hand, the protective role of this gene
marker was evident only in the larger lesions, which
could partly be explained by the coexistence in the
smaller wounds of whole constellations of stronger and
unknown protective factors or lack stronger risk factors.
Both of these situations might simply overcome the gene
marker role. Conversely, larger wounds might possess
biologic agents that may inhibit wound healing but also
prevent systemic infections, and thus, the individual
escapes systematic illness.13 All of this could allow the
lesion to progress and the gene to fully express its action.
Basically, this may have a clinical sense considering that a
complete linear relationship does not exist between
Table III. Healing time and ulcer area dimension in the w
FXIII Variant FXIII genotype n H
FXIII-V34L VV 48 10
VL  LL 43 6
FXIII-P564L PP 53 8
PL  LL 38 7
Total 91 8
Data are mean  SD.
Note: the mean HT (5.7  1.9 weeks) and mean ulcer area (2.83  1.3 cm
the wild types (P  .005 and P  .003, respectively).
*Healing time (HT) comparison.
†Ulcer area comparison.
Table IV. Healing time and ulcer area dimension in cases
by FXIII genotypes
FXIII variant FXIII genotype n
HT  median value (8.0 weeks)
FXIII-V34L VV 36
VL  LL 16
FXIII-P564L PP 29
PL  LL 23
Total 52
HT  median value (8.0 weeks)
FXIII-V34L VV 12
VL  LL 27
FXIIIP-564L PP 24
PL  LL 15
Total 39
Data are mean  SD.
*Healing time (HT) comparison.
†Ulcer area comparison.wound area and healing failure. The magnitude of thenonhealing risk initially increases rapidly for large
wounds, but it diminishes with the largest ones.13
Also of importance is that all of the patients in our
survey were completely hemodynamically corrected by
surgery. Therefore, the essential but insufficient factor
for skin lesion establishment was eliminated. This could
account in part for the following objection: why a ge-
netic factor (congenital by definition) should be protec-
tive (ie, FXIII-V34L on healing time) only after a lesion
becomes larger and not prevent it from happening in the
first place? Similarly, one could ask why a gene risk factor
for ulcer establishment (ie, HFE-C282Y) did not affect
healing time or lesion size in our survey of postoperative
patients?
One answer can well explain both objections: once
superficial venous reflux was corrected and a normal
circulation was restored, many proliferating factors can
reach the débrided wound. Among these, FXIII
strengthens the extracellular matrix against unrestrained
matrix metalloproteases proteolysis, favoring in turn fi-
broblast migration and proliferation and promoting neo-
angiogenesis and healing.15,30-34 The quality and degree
of these actions may be strictly dependent on the associ-
ated gene variants.16 It could be hypothesized that a
cohort of cases stratified by FXIII genotypes
eks Ulcer area (cm2) P* P†
6.5 13.1  24.5 .0001 0.029
3.4 6.0  6.2
6.2 12.0  23.4 0.19 0.064
4.7 6.7  7.0
5.7 9.7  18.5
the 564LL homozygotes were both significantly lower than those found in
healing time above and below the median value stratified
HT weeks Ulcer area (cm2) P* P†
12.5  6.2 16.5  21.7 0.017 0.08
9.5  3.4 9.6  8.3
12.7  6.0 19.0  30.2 0.051 0.043
10.2  4.9 8.9  8.6
11.6  5.6 14.4  23.5
4.3  0.7 4.1  3.2 0.33 0.23
4.0  0.1 3.4  1.7
4.0  0.4 3.6  2.5 0.37 0.42
4.1  0.5 3.7  1.9
4.1  0.5 3.61  2.3hole
T we
.6 
.2 
.9 
.8 
.5 
2) ofwithsignificantly higher FXIII activity (ie, that of the L34
tween
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healing by improving the above-mentioned tasks and
thus shortening the wound closure time. Contextually, a
Fig 4. Relationships between mean healing time and d
chronic venous ulcers is shown and the subgroups carryin
indicate patients with FXIII-VL34 or FXIII-LL34 genot
or FXIII-LL564 genotype. The lines and values show
deviation. P values indicate the statistical significance be
Fig 5. Healing time distribution in two subgroups of patients with
chronic venous ulcers carrying the FXIII-VV34/PP564 double wild
type (WT) genotype, and the FXIII-VL/LL34PL/LL564 genotype
(double carriers), respectively. The line and value shown indicate the
different mean healing times and standard deviation. The P value indi-
cates the statistical significance between the twomean healing times.restored venous drainage gets rid of local iron overload,drastically lowering the possibility that HFE-mutated
phagocytes, losing the ability to counteract the intracel-
lular iron export, generate locally free iron and free
radicals and leading to matrix breakdown and skin le-
sions.14,15,35 This would avoid both the detrimental
effects of free radicals and hyper-proteolysis on extracel-
lular matrix components contrasting, in turn, cell
death.15,31
CONCLUSIONS
Although the number of actors involved in the etiol-
ogy of chronic wounds is extremely high and the above
explanations may just partly account for the complex
etiology of CVU, our study furnishes a good example of
gene-gene and gene-environment interactions for this
multifactorial disorder. Our results, for the first time,
could pave the way to single out in advance categories of
nt FXIII genotypes. The whole cohort of patients with
FXIII-V34L and FXIII-P564L genotypes. L34 carriers
nd L564 carriers indicate patients with the FXIII-PL564
dicate the different mean healing times and standard
mean healing times for each specific FXIII genotype.
Table V. Combined effects of HFE-C282Y and FXIII-
V34L polymorphism on ulcer healing time
HFEC282Y
(n  91)
FXIII-V34L healing time
(weeks)
PVV VLLL
CC 10.1  6.2 6.44  3.9 .0014
n  81 (89%) n  45 n  36
CY 14.6  10 7.4  5.8 .08
n  10 (11%) n  3 n  7iffere
g the
ype, a
n inpatients at increased risk and to address tailored strate-
JOURNAL OF VASCULAR SURGERY
Volume 44, Number 3 Gemmati et al 561gies of treatment, such as priority for surgical correction
of superficial venous reflux.
Future multicenter molecular investigations could
identify groups of molecular markers responsible for
chronic inhibition of a wound to heal, allowing clinicians
the opportunity to develop tailored therapies, design pre-
vention programs, and target specific surgical interventions
in the view of a new and alternative concept of treatment
based on pharmacogenomics.
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